Assembly Biosciences Gains Favor as Clinical Data Prompts Analyst Upgrades

Growing optimism surrounds Assembly Biosciences following the release of compelling interim data from its Phase 1b study targeting herpes simplex virus (HSV). The promising results have drawn increased scrutiny from market analysts, leading several prominent firms to reaffirm bullish ratings and adjust their price targets upward.

The catalyst for this renewed interest stems from the efficacy profile of the company’s helicase-primase inhibitor candidates. Detailed study data revealed a substantial reduction in viral shedding and lesion rates.

Candidate ABI-1179, administered weekly, demonstrated a 98 percent reduction in viral shedding compared to placebo. Furthermore, it achieved a 91 percent decrease in the rate of confirmed lesions. Separately, the monthly therapy ABI-5366 Read more...